1. South Korea Stocks

  2. •

    Industrials

  3. •

    Industrial - Machinery
GemVax&KAEL Co.,Ltd

GemVax&KAEL Co.,Ltd

082270.KQ
GemVax&KAEL Co.,LtdKR flagKOSDAQ
11,360.00
KRW
-40.00
- -
499.33BMarket Cap

Total Valuation

GemVax&KAEL Co.,Ltd carries a market capitalization of 499.33B, placing it among publicly traded companies globally. Its enterprise value stands at 1.47T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap499.33B
Enterprise Value1.47T

Share Statistics

GemVax&KAEL Co.,Ltd currently has 43.95M shares outstanding.

Shares Outstanding43.95M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 16.52, and the price-to-book ratio stands at -24.98.

PE RatioN/A
PS Ratio16.52
PB Ratio-24.98
P/TBV Ratio18.66
P/FCF Ratio797.89
P/OCF Ratio-2,257.78

Enterprise Valuation

On an enterprise value basis, GemVax&KAEL Co.,Ltd trades at an EV/EBITDA multiple of 256.47 and an EV/FCF ratio of 163.84. The EV/Sales ratio of 16.86 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 256.47 provides insight into valuation relative to core operating earnings.

EV / Sales16.86
EV / EBITDA256.47
EV / EBIT256.47
EV / FCF163.84

Financial Position

GemVax&KAEL Co.,Ltd maintains a current ratio of 1.18, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.93, indicating elevated leverage, while an interest coverage ratio of 0.90 demonstrates limited ability to service its debt obligations.

Current Ratio1.18
Quick Ratio0.61
Debt / Equity71.93
Debt / EBITDA10.11
Interest Coverage0.90

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-2.34
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover5.40

Taxes

Income Tax439.57M
Effective Tax RateN/A

Stock Price Statistics

GemVax&KAEL Co.,Ltd's stock has declined approximately -79.85816% over the past 52 weeks. The 50-day moving average sits at 16,802.20, while the 200-day moving average is 32,594.48.

Beta (5Y)N/A
52-Week Price Change-79.85816%
50-Day Moving Average16,802.20
200-Day Moving Average32,594.48
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, GemVax&KAEL Co.,Ltd generated 87.41B in revenue and converted that into -3.94B in net income, yielding earnings per share of -92.74. EBITDA reached 5.74B, while operating income came in at 5.74B.

Revenue87.41B
Gross Profit35.89B
Operating Income5.74B
Pretax Income-3.51B
Net Income-3.94B
EBITDA5.74B
EBIT5.74B
Earnings Per Share (EPS)-92.74

Balance Sheet

GemVax&KAEL Co.,Ltd holds 28.66B in cash and equivalents against 58.07B in total debt, resulting in a net debt position of 33.62B. Total book value stands at -57.82B, with working capital of 8.22B providing operational flexibility.

Cash & Cash Equivalents28.66B
Total Debt58.07B
Net Debt33.62B
Equity (Book Value)-57.82B
Book Value Per Share-1,359.32
Working Capital8.22B

Cash Flow

GemVax&KAEL Co.,Ltd produced -639.57M in operating cash flow over the past twelve months. After subtracting -2.45B in capital expenditures, free cash flow totaled -3.09B - equivalent to -72.62 per share.

Operating Cash Flow-639.57M
Capital Expenditures-2.45B
Free Cash Flow-3.09B
FCF Per Share-72.62

Margins

GemVax&KAEL Co.,Ltd operates with a gross margin of 41.05, reflecting its pricing power and cost economics. The operating margin of 6.57 and net profit margin of -4.51 provide insight into operational efficiency.

Gross Margin41.05
Operating Margin6.57
Pretax Margin-4.01
Profit Margin-4.51
EBITDA Margin6.57

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-1.05
FCF Yield0.13

Scores

GemVax&KAEL Co.,Ltd posts an Altman Z-Score of 9.10, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.10